U.S. markets close in 5 hours 32 minutes
  • S&P 500

    4,633.91
    +66.91 (+1.47%)
     
  • Dow 30

    34,872.90
    +389.18 (+1.13%)
     
  • Nasdaq

    15,733.65
    +195.96 (+1.26%)
     
  • Russell 2000

    2,247.97
    +49.06 (+2.23%)
     
  • Crude Oil

    68.49
    +2.31 (+3.49%)
     
  • Gold

    1,786.30
    +9.80 (+0.55%)
     
  • Silver

    22.67
    -0.15 (-0.64%)
     
  • EUR/USD

    1.1343
    +0.0004 (+0.03%)
     
  • 10-Yr Bond

    1.4900
    +0.0470 (+3.26%)
     
  • GBP/USD

    1.3322
    +0.0020 (+0.15%)
     
  • USD/JPY

    112.9920
    -0.1880 (-0.17%)
     
  • BTC-USD

    58,530.88
    -427.94 (-0.73%)
     
  • CMC Crypto 200

    1,491.41
    +22.33 (+1.52%)
     
  • FTSE 100

    7,135.57
    +76.12 (+1.08%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

Shareholder Alert: Ademi LLP investigates whether Adamas Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Supernus

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Adamas (Nasdaq: ADMS), for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus.

AdemiLogo (PRNewsfoto/Ademi LLP)
AdemiLogo (PRNewsfoto/Ademi LLP)

Click here to learn how to join the action: https://www.ademilaw.com/case/adamas-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

Ademi LLP alleges Adamas' financial outlook and prospects are excellent and yet Adamas shareholders will receive only $8.10 per share in cash (or an aggregate of approximately $400 million), payable at closing plus two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (or an aggregate of approximately $50 million), for a total consideration of $9.10 per share in cash (or an aggregate of approximately $450 million). The first CVR, worth $0.50 per share, is payable upon achieving net sales of GOCOVRI® of $150 million in any four consecutive quarters between closing and the end of 2024. The second CVR, worth $0.50 per share, is payable upon achieving net sales of GOCOVRI of $225 million in any four consecutive quarters between closing and the end of 2025. The merger agreement unreasonably limits competing bids for Adamas by prohibiting solicitation of further bids, and imposing a significant penalty if Adamas accepts a superior bid. Adamas insiders will receive substantial benefits as part of change of control arrangements. We are investigating the conduct of Adamas' board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Adamas.

If you own Adamas common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/adamas-pharmaceuticals-inc.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-adamas-pharmaceuticals-inc-has-obtained-a-fair-price-in-its-transaction-with-supernus-301397028.html

SOURCE Ademi LLP